Skip to content
Trial Eligibility
Menu

Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques

NCT02784210

This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

Background: Multiple sclerosis (MS) affects the brain, spinal cord, and optic nerves. MS lesions can appear on the MRI (magnetic resonance imaging) scans in many ways. Sometimes they light up from the outer edge and fill inward. This is called ring enhancement. Researchers think this type of lesion may not heal as well as others. Corticosteroids are the standard treatment to reduce symptoms of MS relapse. But there is no standard treatment for people with enhancing MS lesions without signs of MS relapse.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Multiple Sclerosis

Eligibility basics and study details

Study type
Interventional
Phase
Phase 2
Ages
18 to 120 years
Sex
All
Healthy volunteers
Not accepted
Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Last updated on ClinicalTrials.gov
October 5, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

Maryland · 1

  • National Institutes of Health Clinical Center · Bethesda, MD

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.